+ Larger Font | - Smaller Font
Share


Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Amicus Therapeutics To Announce Full Year 2016 Financial Results And Corporate Updates On March 1 2017 is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.
Search RobinsPost News & Noticias


Press Release Amicus Therapeutics To Announce Full Year 2016 Financial Results And Corporate Updates On March 1 2017 | RobinsPost News & Noticias

Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates


Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold ® Guidance on Continued Strong Demand Strong ... Read More

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update


March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics ... for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business ... Read More

Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates


Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In ... Alzheimer's disease (AD). In March 2024, Vivoryon announced topline ... Read More

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates


Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHATwo patients ... Read More

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on ...


April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics ... will report first quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Thursday, May 2 ... Read More

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates


today announced first quarter 2024 financial results, provided corporate updates and announced a transition in its leadership. Florian Brand (“Mr. Brand”), Co-Founder and current CEO ... Read More

Capital and Regional to Announce Full Year 2023 Results and Adjusts Dividend Schedule


has announced it will release its full year results for the period ending December 30, 2023, on Tuesday, April 30, 2024. The company will host an in-person presentation for analysts and investors ... Read More

Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates


Full-year revenue guidance ... Conference Call and Webcast Amicus Therapeutics will host a conference call and audio webcast today, May 9, 2024, at 8:30 a.m. ET to discuss the first quarter 2024 ... Read More

Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates


Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat ... L inhibitors with good blood brain barrier penetration. Corporate Development Updates In March 2024, ... Read More

Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates


PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for ... Read More

Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates


PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics ... announced financial results for the first quarter ended March 31, 2024. “Amicus delivered a great start to the year ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus